Iloprost has been shown to minimize skeletal muscle necrosis when administered before the onset of ischemia in animal experiments, possibly by preventing neutrophil activation. Since patients with acute limb ischemia are seen after the process has begun, we investigated whether iloprost can be protective when given only during reperfusion. After anesthesia, 18 adult mongrel dogs underwent a standard isolated gracilis muscle preparation. In six control animals (group I) the gracilis muscle was subjected to 6 hours of ischemia followed by 48 hours of reperfusion. Group II animals (n = 6) received intravenous infusion of iloprost at a dose of 0.45 μg/kg/hr beginning 1 hour before the onset of muscle ischemia and throughout the experiment (6 hours of ischemia and 1 hour of reperfusion). In addition to the continuous infusion, they received 0.45 μg/kg intravenous boluses of iloprost 10 minutes before the induction of ischemia and 10 minutes before reperfusion. Group III animals (n = 6) had a similar ischemic interval, but were given a bolus of iloprost of 0.45 μg/kg at end ischemia followed by continuous infusion of 0.45 μg/kg/hr for 48 hours during reperfusion. Muscle biopsies were obtained at baseline and after 1 hour of reperfusion in all groups. Additional biopsies were obtained at 48 hours of reperfusion in groups I and III. Myeloperoxidase activity, a marker of neutrophil activation, was measured in all muscle biopsies. At the end of reperfusion, the gracilis muscle was harvested in all animals and weighed. Muscle necrosis was estimated by serial transection, nitroblue tetrazolium histochemical staining followed by computerized planimetry. Iloprost decreased the percentage of muscle necrosis from 58% ± 7% in control animals to 34% ± 3% in group II animals (p < 0.04). However, there was no difference in the percentage of muscle necrosis when iloprost was given during the reperfusion phase only (55% ± 8% vs 58% ± 7% in group III and group I, respectively). Myeloperoxidase activity at 1 hour of reperfusion was higher than the baseline in group II animals (0.10 ± 0.02 vs 0.02 ± 0.01 units/mg tissue protein, p < 0.05). The muscle weight increased significantly at the end of reperfusion in all three groups. However, the percentage increase was not significantly different between the three groups (34% ± 8% vs 32% ± 7% vs 39% ± 12%). Although we confirmed that iloprost decreases muscle necrosis when started before the onset of ischemia, we were unable to show a protective effect when given only during reperfusion. Since there was a statistically significant increase in myeloperoxidase activity after 1 hour of reperfusion, it appears that the protective effect of iloprost is not related to inhibition of neutrophil activation. Contrary to previous belief, iloprost did not prevent a rise in vascular permeability.